Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US8518457B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 10, 2006 |
| Grant date | Aug 27, 2013 |
| Priority date | — |
| Expiry date | Nov 27, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/007
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.